NYSE:ZTSPharmaceuticals
Zoetis (ZTS) Valuation Check as Innovation Day, Dividend Hike and New Feline Drug Shape Growth Outlook
Zoetis (ZTS) just packed a lot into a short stretch, from showcasing a fuller innovation pipeline to lifting its dividend and winning Canadian approval for a new feline pain treatment, all suggesting potential for steadier long term earnings power.
See our latest analysis for Zoetis.
Even with Pipeline Day buzz, a higher dividend and fresh regulatory wins for Portela, the 1 year total shareholder return is still down 32.5%, and the 5 year total shareholder return is negative. This suggests...